DBV Technologies S.A. (0QAJ.L)

4.7347 +0.0967 (+2.08%) As of 06:19PM BST. Market open.

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
https://www.dbv-technologies.com

Sector(s): 
Industry: 
Full-time employees: 104

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel Tassé	CEO & Director	1.14M	N/A	1960
Dr. Pharis Mohideen	Chief Medical Officer	680.63k	N/A	1965
Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.	CFO & Principal Accounting Officer	N/A	N/A	1969
Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.	Chief Operations Officer	N/A	N/A	N/A
Ms. Michele F. Robertson	Chief Legal Officer	N/A	N/A	N/A
Ms. Caroline Daniere	Chief Human Resources Officer & Chief of Staff	N/A	N/A	1975
Dr. Wence Agbotounou	Chief Clinical Trial Officer & Senior VP	N/A	N/A	N/A
Mr. Edward P. Jordan M.B.A.	Senior Vice President of Commercial Operations North America	N/A	N/A	1968
Alan Kerr	Senior VP & Head of Global Regulatory Affairs	N/A	N/A	N/A
Mr. Pascal Wotling	Chief External Manufacturing & Supply Chain Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Corporate governance

DBV Technologies S.A.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.